Familial partial lipodystrophy (FPLD) is characterized by adipose tissue repartitioning with multiple metabolic disturbances, including insulin resistance and dyslipidemia. Classical FPLD results from mutations in LMNA encoding nuclear lamin A/C (FPLD2), but recently some families with partial lipodystrophy and normal LMNA sequence were found to have germline mutations in PPARg (FPLD3). For instance, all four affected subjects in a three-generation Canadian FPLD3 kindred ascertained based upon a clinical diagnosis of partial lipodystrophy were heterozygous for the PPARg F388L mutation, which altered a highly conserved residue within helix 8 of the predicted ligand-binding pocket of PPARg. The mutation was absent from normal subjects, and functional studies showed that the mutant receptor had significantly decreased basal transcriptional activity and impaired stimulation by rosiglitazone, with no evidence of a dominant-negative mechanism. Other reported FPLD3 patients with mutant PPARg were ascertained either directly based on a clinical diagnosis of lipodystrophy (R425C mutation), or based on insulin resistance with subsequent demonstration of lipodystrophy (V290M and P467L mutations). Compared to subjects with mutant LMNA, lipodystrophic subjects with mutant PPARg had less severe adipose involvement, together with more severe clinical and biochemical manifestations of insulin resistance, and more variable response to treatment with thiazolidinediones. Thus, rare natural mutations affecting PPARg ligand binding and/or transactivation functions cause partial lipodystrophy, with associated components that resemble the metabolic syndrome.
Introduction
Disturbed carbohydrate and insulin metabolism with central obesity, dyslipidemia and hypertension is referred to as the 'metabolic syndrome'. 1 The resistance of skeletal muscle, adipose and liver to insulin is a defining feature of this syndrome. The phenotype results from the interaction of environmental factors, such as caloric excess and physical inactivity, with largely unknown genetic susceptibility factors. 1, 2 Clinical definitions for the metabolic syndrome have been proposed by the World Health Organization (WHO) 3 and the National Cholesterol Education Program (NCEP) Expert Panel 4 (Table 1 ). Other groups 5 recommend measuring fasting insulin and glucose as surrogates for insulin resistance and impaired glucose tolerance, respectively. The metabolic syndrome according to these definitions was prospectively associated with development of type 2 diabetes mellitus 6 and both total and cardiovascular mortality. 7 The susceptibility to atherosclerosis is probably related to multiple biochemical and metabolic disturbances that occur together with insulin resistance. 2, [8] [9] [10] Monogenic human models of insulin resistance differ with respect to the extent that they recapitulate the disturbances seen in the common metabolic syndrome. Insulin resistance is usually extreme in these monogenic syndromes, as defined anecdotally or by sporadic euglycemic clamp studies. However, monogenic syndromes might help to improve our understanding of the common metabolic syndrome, just as monogenic dyslipidemias played a key role in advancing our knowledge of common dyslipidemia.
Inherited lipodystrophies: monogenic models of insulin resistance Lipodystrophic patients display loss of fat tissue stores in some anatomical sites, frequently with excess fat accumulation in nondystrophic adipose tissue and in unusual sites as liver and muscle. Several types of lipodystrophy have been characterized at the molecular genetic level, including Dunnigan-type familial partial lipodystrophy (FPLD), mandibuloacral dysplasia (MAD), overlap syndromes of partial lipodystrophy with cardiomyopathy and Berardinelli-Seip congenital generalized lipodystrophy. The genetic lipodystrophies have additional interest because they may act as models for drug-induced lipodystrophy, such as the lipodystrophy syndrome that is associated with the use of highly active antiretroviral treatment.
LMNA mutations in partial lipodystrophy (FPLD2) Dunnigan and Koebberling 11 described patients who lost subcutaneous fat from extremities and the gluteal region during puberty, resulting in prominent, well-defined musculature, with sparing of depots in the face, neck, axillae, back, labia majora and intra-abdominally. Imaging has shown that such patients have loss of subcutaneous fat, but preservation of inter-and intramuscular, intraabdominal, intrathoracic and bone marrow fat. 12 The biochemical hallmark of FPLD2 is insulin resistance, with diabetes presenting later. Dyslipidemia and hypertension are common. Other findings variably include acanthosis nigricans, hirsutism, menstrual abnormalities and polycystic ovaries. After mapping the FPLD2 locus to chromosome 1q21-q22, 13 clinical analogy with Emery-Dreifuss muscular dystrophy 14 led to identification of a mutation in the carboxy-terminus of LMNA encoding nuclear lamin A/C. 15 Studies in extended FPLD2 kindreds showed changes that were similar to those seen in the common metabolic syndrome, including elevated plasma triglycerides (TG), free fatty acids and C-reactive protein (CRP), with depressed high-density lipoprotein (HDL) cholesterol. 16 Furthermore, the biochemical profile in FPLD2 includes low-serum leptin and adiponectin. 16, 17 FPLD2 subjects with mutant LMNA, especially women, were also at risk for atherosclerosis. 17 At least seven diseases result from mutant LMNA, 18 including some that have lipodystrophy as a clinical feature, such as MAD (MIM 248370) and progeria (MIM 176670).
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Some LMNA mutations give rise to 'overlap syndromes' characterized by dystrophy in adipose tissue, cardiac myocytes and/or skeletal myocytes. 20 The mechanism(s) by which specific LMNA mutations cause specific tissue involvement and clinical manifestations is unclear.
PPARc mutations in partial lipodystrophy (FPLD3)
PPARg encodes peroxisome proliferator-activated receptor gamma (PPAR-g), a nuclear receptor that induces transcription of genes involved in insulin sensitivity, adipocyte differentiation and inflammation. 21 PPAR-g mediates the pharmacological enhancement of insulin signaling by thiazolidinedione (TZD) drugs. 21 As PPAR-g has an important role in adipocyte biology, PPARg was a good functional candidate gene for lipodystrophy in families with normal LMNA sequence. We discovered PPARg F388L in a three-generation Canadian lipodystrophy kindred, 22 in whom LMNA sequence was normal. The mutation was absent from 520 normal alleles and co-segregated with the lipodystrophy phenotype. In the absence of ligand, the in vitro transcriptional activity of the mutant receptor was three-fold lower than wild-type receptor. However, wild-type and mutant receptors had similar transcriptional activities in the presence of a saturating amount of rosiglitazone. Dose-response curves showed that F388L caused a four-fold rightward shift in the EC50 for PPARg-mediated transcriptional activation, suggesting reduced ligand affinity. The F388L mutation had neither reduced protein expression nor dominant-negative activity against the wild-type receptor. F388L was within helix 8 of the ligand-binding pocket of PPARg, altering a residue that was conserved across all members of the PPAR gene family, and across all species. Low basal activity of the mutant receptor could have been caused either by reduced affinity for a subsaturating amount of the endogenous ligand, or by a disrupted interaction with transcriptional cofactors that mediate basal transcriptional activity. Our demonstration that dysfunctional PPAR-g caused partial lipodystrophy with associated metabolic abnormalities was an important clarification of the impression from earlier studies that PPARg mutations did not cause lipodystrophy, and that lipodystrophic subjects did not have germline PPARg mutations. 23 For instance, heterozygosity for PPARg R115Q was reported in nonlipodystrophic subjects ascertained based upon marked obesity and diabetes. 24 However, the increased adiposity was postulated to have resulted from a gain-of-function, with increased receptor transactivation due to P115Q, inferred because phosphorylation of Ser114 reduced the ability of the receptor to mediate adipocyte differentiation and lipid accumulation. 25, 26 Heterozygosity for either PPARg V290M or P467L was initially reported in nonlipodystrophic subjects with severe insulin resistance. 27 However, later re-evaluation of subjects with PPARg V290M or P467L showed loss of subcutaneous limb fat and atrophy of buttock fat, confirming that mutant PPARg causes lipodystrophy. 28 Heterozygosity for PPARg R425C was found in another patient who was ascertained based on a clinical diagnosis of partial lipodystrophy. 29 However, PPARg R425C was not assessed and there was no demonstration of germline transmission. 29 Nonetheless, these findings in aggregate indicated that loss-of-function mutations causing PPARg deficiency result in partial lipodystrophy. An important question is whether the cluster of metabolic abnormalities follows primarily from the adipose loss or whether the PPARg mutations themselves have other independent effects in various target tissues. One clue may come from careful evaluation of phenotypic distinctions between partial lipodystrophy due to mutant PPARg (FPLD3) and that due to mutant LMNA (FPLD2).
Comparison of PPARc and LMNA forms of partial lipodystrophy Table 2 shows the clinical features compiled from subjects with two molecular forms of lipodystrophy: (1) diabetic and nondiabetic subjects from the extended Canadian FPLD2 family with LMNA R482Q, 16, 17 and (2) FPLD3 patients with mutant PPARg. 22, 27, 29 All subjects had European ethnicity.
Comparisons of fold changes in quantitative traits were against normal matched family controls for LMNA R482Q 16, 17 and PPARg F388L 22 and against the normal reference ranges for other subjects. Qualitative assessment of fat distribution indicated differences between the two molecular types of lipodystrophy. Specifically, there were no limb or gluteal fat stores in LMNA R482Q carriers, while PPARg mutation carriers had some upper arm and gluteal fat. The age of diabetes onset was lower in PPARg mutation carriers (36.478.0 y (mean7s.e.)) than in LMNA mutation carriers (mean 41.274.3 y). Patients with both molecular types of partial lipodystrophy had hypertension, which was particularly severe with some PPARg mutations. Acanthosis nigricans, hepatic steatosis and polycystic ovarian disease were present in both molecular forms of lipodystrophy, and, while presentation was variable, these features appeared to be more prevalent in the PPARg mutation carriers. Similarly, hirsutism was more prevalent among carriers of mutant PPARg than of mutant LMNA. LMNA R482Q was associated with early coronary heart disease, while among the PPARg mutations, only F388L was associated with early coronary heart disease. 17, 22 Body mass index was relatively normal, emphasizing that these patients show abnormal fat distribution and not increased fat mass. Elevated TG and lower HDL were ubiquitous among subjects with both molecular types of lipodystrophy. However, mean serum insulin concentrations were increased to a greater degree in carriers of PPARg mutations than in LMNA R482Q mutation carriers. For instance, serum insulin concentration in F388L subjects compared to family members without the mutation was 2.7-fold, but the overall increase in subjects with LMNA mutations was only 1.6-fold. Concentrations of free fatty acids and CRP, where measured, were similarly increased with both forms of lipodystrophy. Concentrations of leptin and adiponectin were variably depressed across lipodystrophic subjects, with marked depression seen in subjects with the 'dominant-negative' PPARg P467L and V290M mutations, compared with very little change in subjects with F388L.
Response to TZD treatment was assessed in a few subjects. In a woman with LMNA R482W, 12 months of treatment with 8 mg daily of rosiglitazone resulted in increased adipose mass, with improvements in serum leptin, glycemic control and insulin sensitivity. 30 A woman with LMNA R482Q whom I have treated for more than 2 y with 8 mg daily of rosiglitazone had marked improvement in all biochemical variables, with no clinically apparent changes in adipose distribution. A man with PPARg P467L treated for 6 months with 8 mg daily of rosiglitazone had increased fat mass, increased adipocytokine concentrations and normalized glycemia. 28 In contrast, a woman with PPARg V290M treated for 6 months with 8 mg daily of rosiglitazone had a less apparent response of anthropometric and glycemic variables to TZD. 28 A woman with PPARg F388L did not respond to 8 mg daily of rosiglitazone, but her glycemia improved over 12 weeks with 16 mg daily of rosiglitazone. Thus, subjects with both molecular lipodystrophy types respond to TZD, with perhaps a better response in the LMNA form. It is difficult to extrapolate from small numbers, but it would appear that FPLD3 due to mutant PPARg compared to FPLD2 due to mutant LMNA is generally associated with: (1) less extensive adipose loss; (2) more severe and/or earlier clinical end points such as acanthosis nigricans, hepatic steatosis, polycystic ovarian disease and hirsutism; (3) more severe hypertension; (4) earlier onset of type 2 diabetes; (5) greater biochemical insulin resistance; (6) pronounced depression of adipocytokines in some cases; (7) variable biochemical response to TZDs. The early atherosclerosis that was clearly seen in women with LMNA R482Q was less definitively shown in the small number of PPARg mutation carriers so far reported. In aggregate, it would appear that the clinical and biochemical derangement in subjects with PPARg mutations is out of proportion to the extent of lipodystrophy when compared with subjects with mutant LMNA, implying that PPARg mutations may have independent effects on metabolism.
Conclusions
The findings from patients with rare loss-of-function mutations in PPARg indicate that inherited partial lipodystrophy is clinically and genetically heterogeneous, extending the spectrum of metabolic phenotypes caused by PPARg mutations. The findings are consistent with the idea that PPARg plays a key role in adipogenesis. However, comparison with lipodystrophy due to mutant LMNA suggests that the clinical presentation seen in patients with mutant PPARg is associated with additional mechanisms contributing to insulin resistance and metabolic changes beyond those that can be attributed solely to the loss of adipose tissue.
